Why Staying Private Too Long Can Be Dangerous

Could a $9 billion healthcare empire vanish in a single day? The distinction between private vs public companies allowed Theranos to operate for over a decade without showing a single audited financial statement to the federal government. This lack of transparency turned a Silicon Valley unicorn into a cautionary tale about the dangers of avoiding oversight.

Elizabeth Holmes successfully built a massive valuation while keeping her technology hidden from the public eye. By staying private, she ensured that the standard investigative mechanisms of the market couldn't touch her. This strategy allowed her to bypass the rigorous disclosure rules that protect investors and patients in the public sector.

Using the Private Shield as a Competitive Advantage

Staying private isn't just about ownership; it's a strategic choice to limit who can see the inner workings of a business. In his investigative work Bad Blood, John Carreyrou explains how Elizabeth Holmes used this status to hide the fact that her technology simply didn't work. While public companies must reveal their failures every ninety days, private firms can keep their secrets for years.

This concept matters because it creates a massive information gap between the founder and the investor. In the case of Theranos, the company raised hundreds of millions of dollars without ever being forced to prove its scientific claims to a neutral third party. Founders often argue they need this privacy to protect trade secrets, but it frequently becomes a way to protect institutional lies.

How Information Silos Hide the Truth about Private vs Public Companies

The fundamental difference between private vs public companies is who has the right to see the data. Publicly traded companies are legally required to file 10-K and 10-Q reports with the SEC. These documents are audited by independent firms, providing a baseline of truth for anyone looking to invest. Private companies, however, operate in the shadows, sharing only what they choose with a select group of venture capitalists.

Theranos took this privacy to an extreme level by siloing its own departments. Engineers weren't allowed to talk to chemists, and the finance department had no access to clinical data. This internal secrecy mirrored the company's external stance toward the market. It's a structure that prevents anyone from seeing the whole picture, making it impossible to identify systemic failures.

Why Famous Board Members Can't Substitute for SEC Regulation

Elizabeth Holmes didn't rely on data to prove her worth; she relied on prestige. She filled her board with legendary figures like George Shultz, Henry Kissinger, and James Mattis. These men were giants of the American establishment, but they weren't medical experts. Their presence gave the company a "stamp of legitimacy" that replaced the need for rigorous SEC regulation in the eyes of many investors.

This is the prestige trap. Investors often assume that if a former Secretary of State is on the board, the company must be legitimate. However, these luminaries were often just as deceived as the public. They were shown faked demonstrations and given inflated projections while the actual lab work remained hidden behind bulletproof glass and non-disclosure agreements.

The Valuation Trap in Private Markets

When a company stays private, its valuation is based on what the last investor was willing to pay, not the company's actual performance. Theranos reached a $9 billion valuation in 2014 because a handful of hedge funds bought into the hype. There was no public market to "short" the stock or challenge the narrative. This led to a situation where a company could be worth billions on paper while producing almost no revenue.

Partner Fund Management invested $96 million into Theranos at a price of $17 per share based on these private projections. The company told these investors it would generate $1.68 billion in revenue by 2015. In reality, the internal controller's forecast was only $134 million. Without the transparency of a public exchange, these massive discrepancies go unnoticed until it's too late for the capital to be saved.

High-Profile Partnerships and Private Risk

The Theranos story isn't just about internal fraud; it's about how private capital affects massive public retailers. Safeway and Walgreens both signed deals worth hundreds of millions of dollars without performing sufficient due diligence on the core technology. Safeway alone spent $350 million on store renovations to accommodate wellness centers for a product that was still in the prototype phase.

These corporations were blinded by the fear of missing out. They saw a young, charismatic founder and assumed the due diligence had been done by the venture capitalists on Sand Hill Road. By the time Walgreens realized the Edison devices were failing 25 percent of their daily quality-control checks, they had already invested $140 million in fees and loans.

Theranos even used its private status to mislead military leaders. General James Mattis was convinced the technology could be used on the battlefield to save soldiers' lives. He pushed for field tests in Afghanistan, only to be blocked by regulatory experts within the Army who realized the devices weren't cleared by the FDA. The lack of public scrutiny allowed Holmes to maintain this heroic narrative far longer than the facts supported.

How to Protect Your Capital in the Private Market

You don't have to be a billionaire to learn from the Theranos collapse. Whether you're a startup founder or a professional investor, you need to understand the structural risks inherent in private markets. Relying on a founder's charisma or the names on a board of directors is a recipe for catastrophic loss.

1. Demand audited financials from an independent third party. Never accept a founder's internal spreadsheet as the final word on revenue or cash flow. If a company refuses to provide audits from a reputable firm, walk away from the deal immediately.

2. Verify the core technology through a neutral expert. Don't rely on demonstrations controlled by the company. Insist on seeing raw data or having the product tested in an environment where the company can't manipulate the results. If the technology is truly revolutionary, it should withstand the scrutiny of an expert who isn't on the payroll.

3. Look for high employee turnover in key technical roles. At Theranos, senior scientists and lab directors like Ian Gibbons and Alan Beam were constantly marginalized or pushed out. If the people closest to the technology are resigning in clusters, it's a clear sign that the internal reality doesn't match the public marketing.

The Burden of Public Transparency

Critics of the public market often argue that SEC regulation is too burdensome for young companies. They claim that quarterly reporting cycles force founders to focus on short-term gains rather than long-term innovation. This argument suggests that staying private allows for a "purer" focus on building a world-changing product without the distraction of a fluctuating stock price.

There's some truth to the idea that public markets can be impatient. However, the Theranos case proves that the alternative is often much worse. Without the requirement for transparency, a company can burn through billions of dollars of capital while producing nothing but error-prone test results. The "burden" of regulation is actually a safeguard that keeps the entire financial ecosystem honest.

Investors in private vs public companies must realize that privacy is a double-edged sword. While it may protect a company from competitors, it also protects a fraudulent founder from the law. The best protection for any stakeholder is a healthy dose of skepticism and a demand for verifiable data over charismatic stories.

Real business growth depends on transparency and technical truth. Theranos was a $9 billion phantom that only existed because it hid from the light of public markets. Request a full audit and verified technical data before committing any resources to a private venture.